Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In June 2015, he launched and incorporated IDEAYA Biosciences as its first employee and Chief Executive Officer and led the company’s IPO in May 2019 (NASDAQ: IDYA). From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, which he led through its acquisition by Bristol-Myers Squibb in April 2015, and then served as Chief Operating Officer at FLX Bio (renamed RAPT Therapeutics, NASDAQ: RAPT), a spinout of Flexus Biosciences. From 2010 to 2014, including through the approvals of Kyprolis® and Stivarga® and its acquisition by Amgen in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Yujiro served as Vice President, Business Development, Senior Vice President, Business Development, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which discovered the protease inhibitors contained in Viekira Pak and Mavyret™, both of which received Breakthrough Therapy designation and approval by the FDA. He earlier served in roles at McKinsey, ImClone and Columbia Medical School.
Yujiro obtained his M.B.A. at the University of Pennsylvania where he was a Henry J. Kaiser recipient and was awarded 1st prize at the 2nd Annual Wharton Business Plan competition out of 226 business plans. He obtained his B.A. in chemistry at Colorado College and did undergraduate studies in chemistry and biology at Oxford University. He served on the Board of Directors at Xencor (NASDAQ: XNCR) from 2015 to 2022 and serves on the Board of Directors at Enanta Pharmaceuticals (NASDAQ: ENTA) and as Board Member at the Moores Cancer Center at the University of California, San Diego.
What is Yujiro S. Hata's net worth?
The estimated net worth of Yujiro S. Hata is at least $17.36 million as of May 16th, 2024. Mr. Hata owns 677,887 shares of IDEAYA Biosciences stock worth more than $17,360,686 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Hata may own. Additionally, Mr. Hata receives a salary of $912,000.00 as President, CEO & Director at IDEAYA Biosciences. Learn More about Yujiro S. Hata's net worth.
How old is Yujiro S. Hata?
What is Yujiro S. Hata's salary?
How do I contact Yujiro S. Hata?
Has Yujiro S. Hata been buying or selling shares of IDEAYA Biosciences?
Yujiro S. Hata has not been actively trading shares of IDEAYA Biosciences within the last three months. Most recently, Yujiro S. Hata sold 34,433 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $41.81, for a transaction totalling $1,439,643.73. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares of the company's stock, valued at $28,342,455.47. Learn More on Yujiro S. Hata's trading history.
Who are IDEAYA Biosciences' active insiders?
Are insiders buying or selling shares of IDEAYA Biosciences?
In the last twelve months, insiders at the sold shares 9 times. They sold a total of 224,201 shares worth more than $9,168,290.29. The most recent insider tranaction occured on May, 29th when insider Michael Anthony White sold 28,500 shares worth more than $1,032,840.00. Insiders at IDEAYA Biosciences own 3.5% of the company.
Learn More about insider trades at IDEAYA Biosciences. Information on this page was last updated on 5/29/2024.
